Autolus Therapeutics Spon Ads Ea Rep 1 Ord Shs (AUTL) Stock
Early stage biotech developing engineered cell cancer treatments. Here's the price, business snapshot, and what's worth knowing about Autolus Therapeutics Spon Ads Ea Rep 1 Ord Shs in June 2026.
Autolus Therapeutics plc (AUTL) is a clinical‑stage biotechnology company developing engineered T‑cell (CAR‑T) therapies for cancer. With a market capitalisation of roughly $433.8m, it is a small‑cap, research‑intensive group whose value depends heavily on trial results, regulatory decisions and potential partnerships. Investors should know that Autolus has no broad commercial revenue stream today and that clinical milestones and safety data are binary events that can drive significant share‑price moves. The company’s outlook hinges on successful patient outcomes, cost controls and access to funding; this makes the stock suitable primarily for investors comfortable with high volatility, long time horizons and the possibility of capital loss. This summary is for educational purposes only and not personalised advice — consider diversification and professional guidance when assessing suitability.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Autolus Therapeutics stock with a target price of $9.27, indicating strong potential growth.
Financial Health
Autolus Therapeutics is generating moderate revenue, but its financial health may need improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring AUTL
Oncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Major trial readouts and regulatory decisions can change valuation quickly, offering potential upside but bringing binary risk.
Targeted cancer focus
Programmes aim at specific haematological cancers and possibly solid tumours; scientific progress matters more than short‑term market moves.
Cutting‑edge engineering
Autolus uses advanced T‑cell engineering techniques, which could deliver breakthroughs, though development is costly and uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
